“Use of the 40-Gene Expression Profile (40-GEP) Test in Medicare-Eligible Patients Diagnosed with Cutaneous Squamous Cell Carcinoma (cSCC) to Guide Adjuvant Radiation Therapy (ART) Decisions Leads to a Significant Reduction in Healthcare Costs ” (2024) SKIN The Journal of Cutaneous Medicine, 8(1), p. s336. doi:10.25251/skin.8.supp.336.